What Is ASO Therapy?
An antisense oligonucleotide, or ASO, is a short lab-made strand designed to bind to a specific RNA message. RNA is the working copy cells use after DNA has been read. By binding to RNA, an ASO can sometimes lower the amount of a harmful message, change how the message is spliced, or help the cell make a more useful version of a protein.
Plain-English explanation
An antisense oligonucleotide, or ASO, is a short lab-made strand designed to bind to a specific RNA message. RNA is the working copy cells use after DNA has been read. By binding to RNA, an ASO can sometimes lower the amount of a harmful message, change how the message is spliced, or help the cell make a more useful version of a protein.
Why it matters
ASOs can be designed with unusual precision, which makes them important for rare diseases where a specific gene or RNA problem is known. They may also be adjustable over time because many ASOs are repeat-dosed rather than one-time treatments. That can be an advantage, but it also means families must understand delivery, monitoring, and the burden of ongoing treatment.
How it works
Researchers identify the RNA sequence they want to target, design an ASO that can bind to it, and test whether the ASO changes RNA behavior in the intended way. Some ASOs reduce a toxic RNA or protein. Others redirect splicing so the cell includes or skips a piece of RNA. Delivery depends on the disease and tissue: some ASOs are given into spinal fluid for nervous-system disorders, while others are delivered systemically.
Key terms
Related interviews and articles
Inside the Fight to Cure Rett Syndrome – Monica Coenraads Interview
Monica Coenraads
Monica Coenraads, founder and CEO of the Rett Syndrome Research Trust (RSRT), has led the charge to cure Rett Syndrome—raising over $123 million and driving multiple gene therapy programs now in clinical trials. In this in-depth conversa...
What AI Drug Discovery Could Mean for Rare Disease Families
AI drug discovery is entering a new phase: not just better software, but a new industrial stack linking frontier models, pharma data, robotics, and real experiments.
Why it matters: Rare disease research often starts with small datasets, limited funding, urgent timelines, and difficult trial design. AI-linked discovery systems could help researchers generate stronger candidates and better experiments faster, but families should watch for clinical validation, access, manufacturing, and clear evidence rather than hype.
Source: GENEration Hope editorial analysis